top of page

News and Events

May 2024: Participating at the BioMed conference in Tel Aviv

May 2023: Participated at the BioMed conference in Tel Aviv

Dec 2022: Short in-vivo trial of the device completed at Mount Sinai. 

June 2022: Completed updated design of the AFL device with our partners from Mount Sinai Medical Center, Bioengineering Department. 

May 2020: KidneyX Redesign Dialysis Phase 2 Honorable Mention

Aug 2019: Presented at the IDEAS conference in Seattle,  https://cdi.washington.edu/ideas/ on Innovation in Dialysis.

April 2019: Winner in the KidneyX Redesign Dialysis prize competition Phase 1

April 2019: 3rd Innovation & Entrepreneurship International Competition, Shenzhen, China. Third Prize, Biology and Life Technology Final

Mar 2018: Selected participant at the 1st China (Ningbo) Global Experts Summit (CGES) http://www.ocstab.net/index.php/en/activities-news/activity-details/the1st-china-ningbo-global-experts-summit-cges

Nov. 2017: Selected participant in the Global Startup Program Asia + in Taipei, Taiwan.  http://www.garageplus.asia/en/startups

Mission Statement: "We believe that entrepreneurs are mission-driven individuals who take actions to realize their dreams and bring a better life to society through innovation."

May 2017: Mixiii Biomed 2017 conference, table in the Start-Up Pavilion.

April 2017: Successful completion of 9-month vascularized tissue in-growth tissue study in rodents.  Study reports by an expert histopathologist, Dr. Abraham Nyska, DVM, Dipl. ECVP, Fellow IATP. Slides prepared by Alizee Pathology, Thurmont, MD. 

Nov 2016: Access for Life a Silver Award Winner of MassChallenge 2016.

Watch: https://www.youtube.com/watch?v=C9_fo75JnXk 

July 2016: Next stage of animal trials commenced at the GLPigs CRO, Assaf Harofeh Medical Center, Rishon Lezion, Israel.

May 2016: Won a place in the MassChallenge Accelerator Program in Jerusalem.

April  2016: Won a EU Horizon 2020 Phase 1 SME Grant. This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 728915.

Jan. 2016:  Pharmes Innovations Limited investment received, which will be used to fund the animal trials. As a result, David Grey has joined the Board of Directors.

 

Dec. 2015: Initial round of the large animal trials, pilot stage,  completed at the GLPigs CRO at Assaf Harofeh Medical Center, Tzrifin, Israel.

 

May 2015: Our CEO, Philip Libman, presented at the Israel Advanced Technology Institute’s Biomed 2015 Conference in Tel Aviv. 

Philip Libman at the Biomed 2024 conference. 

BioMed 2024 table 1.jpg
bottom of page